Drugs affecting lipid metabolism

作者: I. Aursnes

DOI: 10.1016/S0378-6080(00)80050-1

关键词: HypoprothrombinemiaMedicineVitamin K deficiencyEndocrinologyGemfibrozilFenofibrateInternal medicineOsteomalaciaCholestyramineVitamin D and neurologyNiacin

摘要: Publisher Summary This chapter discusses several drugs that affect lipid metabolism. Adverse events are essentially the same with all fibrates. During short-term treatment, they generally mild or absent. The long-term effects still uncertain. Fibrates produce bile is supersaturated cholesterol. Although gallstones frequently seen clofibrate, no excess frequency has been observed fenofibrate. However, individuals liver disease of any type should probably not be advised to take In study discussed in chapter, hypoglycemia a diabetic patient apparently resulted from glyburide combined gemfibrozil. Because fibrates highly bound serum albumin, displace other similarly drugs. Constipation, upper abdominal pain, flatulence, heartburn, and nausea have various degrees. Vitamin K deficiency may theory lead hypoprothrombinemia hence bleeding. A degree osteoporosis osteomalacia can occur because reduced vitamin D absorption. Binding substances present gastrointestinal tract explains interactions cholestyramine, it special importance as concerns K, D, iron. It entirely clear what extent incidence adverse reactions nicotinic acid (niacin) encountered its derivatives. Flushing skin normal reaction high doses until tolerance develops. Some patients experience much more severe vascular sensations heat, throbbing headache, vertigo, faintness, and, sometimes, marked fall blood pressure.

参考文章(135)
Frank D. Mann, The Dynamics of Free Cholesterol Exchange May Be Critical for Endothelial Cell Membranes in the Brain Perspectives in Biology and Medicine. ,vol. 33, pp. 531- 534 ,(1990) , 10.1353/PBM.1990.0048
Richard C. Pasternak, Benet S. Kolman, Unstable myocardial ischemia after the initiation of niacin therapy The American Journal of Cardiology. ,vol. 67, pp. 904- 906 ,(1991) , 10.1016/0002-9149(91)90631-T
Albert Steiner, Burkhard Weisser, Wilhelm Vetter, A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia Drug Safety. ,vol. 6, pp. 118- 130 ,(1991) , 10.2165/00002018-199106020-00003
Karen Kjær, Jørgen Hangaard, Niels E Petersen, Claus Hagen, Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia. European Journal of Endocrinology. ,vol. 126, pp. 229- 232 ,(1992) , 10.1530/ACTA.0.1260229
Silvia Pizarro, Joan Bargay, Pilar D'Agosto, Gemfibrozil-induced impotence. The Lancet. ,vol. 336, pp. 1135- 1135 ,(1990) , 10.1016/0140-6736(90)92618-R
David A. Fisher, Exacerbation of Psoriasis by the Hypolipidemic Agent, Gemfibrozil Archives of Dermatology. ,vol. 124, pp. 854- 855 ,(1988) , 10.1001/ARCHDERM.1988.01670060012006
RH Jay, AC Dickson, DJ Betteridge, Effects of aspirin upon the flushing reaction induced by niceritrol. British Journal of Clinical Pharmacology. ,vol. 29, pp. 120- 122 ,(1990) , 10.1111/J.1365-2125.1990.TB03611.X
R.D. Hildebrand, Lovastatin and Hypospermia Annals of Internal Medicine. ,vol. 112, pp. 549- 550 ,(1990) , 10.7326/0003-4819-112-7-549_2
Eliot Corday, Lars Rydén, Why some physicians have concerns about the cholesterol awareness program Journal of the American College of Cardiology. ,vol. 13, pp. 497- 502 ,(1989) , 10.1016/0735-1097(89)90531-7